Table 1.
Univariate Analysis of Demographics Overall and Between Subjects With or Without Nephrotoxicity
| Overall N = 680 |
With Nephrotoxicity n = 45 |
Without Nephrotoxicity n = 635 |
P Value | |
|---|---|---|---|---|
| Median age (IQR), years | 6.7 (2.2–13.7) | 5.1 (1.5–14.3) | 6.8 (2.4–13.6) | .605 |
| <1, no. (%) | 88 (12.9) | 10 (22.2) | 78 (12.3) | – |
| 1 to <2, no. (%) | 65 (9.6) | 1 (2.2) | 64 (10.1) | – |
| 2 to <12, no. (%) | 305 (44.9) | 19 (42.2) | 286 (45.0) | – |
| ≥12, no. (%) | 222 (32.6) | 15 (33.3) | 207 (32.6) | – |
| Median weight (IQR), kg | 23.1 (12.8–46.7) | 23.4 (12.9–42.4) | 23 (12.8–47.3) | .573 |
| Median ideal body weight (IQR), kg | 23.4 (12.8–38.6) | 21.2 (12.0–37.1) | 23.8 (12.8–38.6) | .508 |
| Median body surface area (IQR), m2 | 0.9 (0.6–1.4) | 0.9 (0.6–1.3) | 0.9 (0.6–1.4) | .525 |
| Median body mass index (IQR), kg/m2 | 17.6 (15.6–21.0) | 17.4 (15.6–22.0) | 17.6 (15.6–20.9) | .932 |
| Race/Ethnicity | .579 | |||
| Hispanic, no. (%) | 247 (36.3) | 16 (35.6) | 231 (36.3) | – |
| White, no. (%) | 90 (13.2) | 6 (13.3) | 84 (13.2) | – |
| African-American, no. (%) | 42 (6.2) | 2 (4.4) | 40 (6.3) | – |
| Asian, no. (%) | 14 (2.1) | 2 (4.4) | 12 (1.9) | – |
| Other/Unknown, no. (%) | 287 (42.2) | 19 (42.2) | 268 (42.2) | – |
| Male gender, no. (%) | 361 (53.1) | 20 (44.4) | 341 (53.7) | .229 |
| Intensive care unit stay, no. (%) | 271 (39.9) | 32 (71.1) | 239 (37.6) | < .001 |
| Concurrent use of nephrotoxic agents, no. (%) | 264 (38.8) | 28 (62.2) | 236 (37.2) | .001 |
| Median baseline serum creatinine (IQR), mg/dL | 0.4 (0.3–0.5) | 0.3 (0.2–0.6) | 0.4 (0.3–0.5) | .380 |
| Mean empiric vancomycin dose ± SD (IQR), mg/kg per day | 46.7 ± 11.6 (39.8–57.2) | 50.2 ± 11.8 (43.5–60.2) | 46.4 ± 11.6 (39.7–59.6) | .033 |
| Every 6 h, no. (%) | 281 (41.3) | 18 (40.0) | 263 (41.4) | – |
| Every 8 h, no. (%) | 343 (50.4) | 26 (57.8) | 317 (49.9) | – |
| Every 12 h, no. (%) | 50 (7.4) | 0 (0) | 50 (7.9) | – |
| Every 16–24 h, no. (%) | 6 (0.9) | 1 (2.2) | 5 (0.8) | – |
| Median duration of vancomycin therapy (IQR), days | 4 (3–7) | 8 (6–11) | 4 (3–7) | < .001 |
Abbreviations: IQR, interquartile range; SD, standard deviation.